Press release

Cinclus Pharma invites to KOL event: insights on clinical practice for erosive Gastroesophageal Reflux Disease (GERD) patients

Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive GERD, as well as the potential of Cinclus Pharma’s drug candidate linaprazan glurate. The event will take place on Thursday, 11 December, 15:00–16:00 CET / 09:00–10:00 AM EST.

Following the presentation, there will be an opportunity to ask questions. A recorded version of the webcast will be available on the company’s website after the event.

For registration and further information about the event, please follow the link below:

Cinclus Pharma Virtual KOL Event - LifeSci Events

About Professor Prateek Sharma
Prateek Sharma, MD, MASGE, FACP, FACG is Professor of Medicine and the Elaine Blaylock Endowed Professor at the Cancer Center in Kansas City, USA. Dr. Sharma has been at the forefront in improving diagnosis and management of GI diseases and cancer, specifically esophageal diseases, GERD, Barrett’s esophagus, imaging, artificial intelligence, digital health, sustainable healthcare and endoscopic treatments. He is a world-renowned physician, teacher, and educator. He has over 550 publications, including guidelines and book chapters, and is regularly invited to present at major national and international meetings. He has published several important textbooks in medicine. Dr. Sharma continues to publish in several high-profile international journals, including the New England Journal of Medicine, JAMA, Annals of Internal Medicine, Gastroenterology, American Journal of Gastroenterology and Gastrointestinal Endoscopy.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.